MAP3K5 and ovarian carcinoma: Overactivation of the PI3K/AKT pathway in the gemcitabine-resistant ovarian cancer cell line, A2870CP, suppresses expression of AKT-inhibited apoptosis signal-regulating kinase 1 (ASK1), resulting in the reduced expression of downstream JNK and p38 to induce MDR [20].